The average one-year price target for ImmunityBio (NasdaqGS:IBRX) has been revised to $11.73 / share. This is an increase of 10.58% from the prior estimate of $10.61 dated December 18, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $5.05 to a high of $25.20 / share. The average price target represents an increase of 315.96% from the latest reported closing price of $2.82 / share.
What is the Fund Sentiment?
There are 391 funds or institutions reporting positions in ImmunityBio. This is an increase of 19 owner(s) or 5.11% in the last quarter. Average portfolio weight of all funds dedicated to IBRX is 0.04%, an increase of 14.40%. Total shares owned by institutions increased in the last three months by 13.80% to 155,874K shares. 
The put/call ratio of IBRX is 0.27, indicating a bullish outlook.
What are Other Shareholders Doing?
Jane Street Group holds 12,836K shares representing 1.30% ownership of the company. In its prior filing, the firm reported owning 7,718K shares , representing an increase of 39.87%. The firm increased its portfolio allocation in IBRX by 19.24% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 7,451K shares representing 0.76% ownership of the company. No change in the last quarter.
Geode Capital Management holds 6,890K shares representing 0.70% ownership of the company. In its prior filing, the firm reported owning 5,777K shares , representing an increase of 16.15%. The firm increased its portfolio allocation in IBRX by 1.15% over the last quarter.
Heights Capital Management holds 6,566K shares representing 0.67% ownership of the company.
IWM - iShares Russell 2000 ETF holds 5,690K shares representing 0.58% ownership of the company. In its prior filing, the firm reported owning 4,049K shares , representing an increase of 28.85%. The firm increased its portfolio allocation in IBRX by 24.46% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
